Fosun Kite Launches China’s First Outcome-based Payment Plan for CAR-T Therapy

Fosun Kite Biotechnology Co. Ltd. on Thursday launched a pay-for-performance plan for its cell therapy aimed at cancer patients. Patients can get a refund of up to 600,000 yuan ($84,300) if the therapy doesn’t work.

This is the first outcome-based payment plan adopted in China for chimeric antigen receptor (CAR) T cell therapy, a new but expensive type of cancer treatment that reprograms patients’ immune system to attack cancer cells.